moving forward active bateman leading trial testing lilly solanezumab roche ganetenerumab 160 people 18 80 years old genetic risk alzheimer symptoms efforts trying determine disease prevented destroying amyloid protein brain damaged damage occurs decades alzheimer researchers suspect antibody trials failed treated people late hypothesis supported lilly finding people mild disease benefit solanezumab latest results demonstrate time humans slowing amyloid deposition slow cognitive decline says eric reiman executive director banner alzheimer institute phoenix arizona important food drug administration said not approve drugs block amyloid deposits sufficient evidence clinical benefit drug company prove cause effect amyloid accumulation alzheimer progression companies benefit says